A detailed history of Avantax Advisory Services, Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Avantax Advisory Services, Inc. holds 106,929 shares of GILD stock, worth $9.46 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
106,929
Previous 97,591 9.57%
Holding current value
$9.46 Million
Previous $6.7 Million 33.86%
% of portfolio
0.06%
Previous 0.05%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$66.59 - $83.99 $621,817 - $784,298
9,338 Added 9.57%
106,929 $8.96 Million
Q2 2024

Aug 09, 2024

BUY
$63.15 - $72.88 $4.05 Million - $4.67 Million
64,119 Added 191.56%
97,591 $6.7 Million
Q1 2024

May 08, 2024

SELL
$71.58 - $87.29 $228,698 - $278,891
-3,195 Reduced 8.71%
33,472 $2.45 Million
Q4 2023

Feb 07, 2024

SELL
$73.27 - $83.09 $352,282 - $399,496
-4,808 Reduced 11.59%
36,667 $2.97 Million
Q3 2023

Nov 07, 2023

SELL
$73.94 - $80.67 $56,268 - $61,389
-761 Reduced 1.8%
41,475 $3.11 Million
Q2 2023

Aug 11, 2023

SELL
$76.01 - $86.7 $155,364 - $177,214
-2,044 Reduced 4.62%
42,236 $3.26 Million
Q1 2023

Apr 28, 2023

BUY
$77.31 - $88.08 $120,758 - $137,580
1,562 Added 3.66%
44,280 $3.67 Million
Q4 2022

Feb 13, 2023

SELL
$62.32 - $89.47 $412,870 - $592,738
-6,625 Reduced 13.43%
42,718 $3.67 Million
Q3 2022

Nov 01, 2022

BUY
$59.54 - $68.01 $424,103 - $484,435
7,123 Added 16.87%
49,343 $3.04 Million
Q2 2022

Aug 02, 2022

BUY
$57.72 - $65.01 $325,252 - $366,331
5,635 Added 15.4%
42,220 $2.61 Million
Q1 2022

Apr 27, 2022

BUY
$57.92 - $72.58 $30,987 - $38,830
535 Added 1.48%
36,585 $2.18 Million
Q4 2021

Jan 24, 2022

SELL
$64.88 - $73.64 $15,765 - $17,894
-243 Reduced 0.67%
36,050 $2.62 Million
Q3 2021

Oct 21, 2021

BUY
$67.69 - $73.03 $580,441 - $626,232
8,575 Added 30.94%
36,293 $2.53 Million
Q2 2021

Jul 29, 2021

BUY
$63.47 - $69.35 $293,993 - $321,229
4,632 Added 20.06%
27,718 $1.91 Million
Q1 2021

May 13, 2021

BUY
$60.0 - $68.46 $93,660 - $106,866
1,561 Added 7.25%
23,086 $1.49 Million
Q4 2020

Jan 22, 2021

SELL
$56.65 - $64.55 $1.91 Million - $2.18 Million
-33,768 Reduced 61.07%
21,525 $1.26 Million
Q3 2020

Oct 14, 2020

BUY
$62.1 - $78.08 $2.07 Million - $2.61 Million
33,381 Added 152.34%
55,293 $3.48 Million
Q2 2020

Aug 06, 2020

BUY
$72.34 - $84.0 $462,107 - $536,592
6,388 Added 41.15%
21,912 $1.69 Million
Q1 2020

Apr 30, 2020

BUY
$62.63 - $80.22 $343,212 - $439,605
5,480 Added 54.56%
15,524 $1.16 Million
Q4 2019

Feb 14, 2020

SELL
$61.62 - $67.78 $119,974 - $131,967
-1,947 Reduced 16.24%
10,044 $650,000
Q3 2019

Nov 08, 2019

BUY
$62.51 - $69.0 $11,564 - $12,765
185 Added 1.57%
11,991 $758,000
Q2 2019

Aug 06, 2019

SELL
$61.87 - $69.38 $13,054 - $14,639
-211 Reduced 1.76%
11,806 $798,000
Q1 2019

May 13, 2019

BUY
$62.53 - $70.05 $22,698 - $25,428
363 Added 3.11%
12,017 $781,000
Q4 2018

Feb 13, 2019

BUY
$60.54 - $79.0 $705,533 - $920,666
11,654 New
11,654 $729,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $111B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Avantax Advisory Services, Inc. Portfolio

Follow Avantax Advisory Services, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avantax Advisory Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Avantax Advisory Services, Inc. with notifications on news.